CD274 and hepatocellular carcinoma: The epigenetic modifier EZH2 has also been shown to suppress IFN-y induced PDL-1 expression in HCC cell lines, thus representing a possible therapeutic target for inhibition and subsequent combination with anti-PD-1/PDL-1 therapy [103].